Recommendation of the President – Hemlibra (emicizumab)

On 12 August 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 115/2025 on the appraisal of drug Hemlibra (emicizumab) under the drug program “Prevention of bleeding in patients with uncomplicated hemophilia A with factor VIII inhibitor (ICD-10: D66)”

Publication in Public Information Bulletin (BIP) >>

=